University of Virginia
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Virginia sits in the top decile of US sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count).
University of Virginia: 449 sponsored US clinical trials, 101 recruiting.
University of Virginia sponsors 449 registered US clinical trials on ClinicalTrials.gov, 101 of them currently recruiting, and 281 completed. 40 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 9 trials.
Top-decile sponsor footprint
University of Virginia ranks in the top decile of sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
281 of 317 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
449 total, page 9 of 9
Pilot Study of Infrared Imaging of Cutaneous Melanoma
NCT00937690
A Gene by Medication Interaction to the Acute Effects of Alcohol
NCT01343628
Determining How Quickly Progesterone Slows LH Pulse Frequency
NCT00594217
The Effect of Transcutaneous Electrical Nerve Stimulation on Quadriceps Central Activation and Gait
NCT00976079
A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization
NCT00570648
Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis
NCT00570960
Effects of Proximal and Distal Tibiofibular Joint Manipulation on Lower Extremity Muscle Activation, Ankle Range of Motion, and Functional Outcome Scores in Individuals With Chronic Ankle Instability
NCT00601471
Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
NCT00681408
Reducing Alcohol Exposed Pregnancy Risk: EARLY Randomized Controlled Trial
NCT01446653
Time Outside Target Oxygen Saturation Range in Preterm Infants and Long Term Outcomes and Preterm Infants
NCT00845624
Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial
NCT00678457
Effectiveness of Internet Cognitive Behavioral Therapy Intervention for Treating Insomnia
NCT00328250
Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma
NCT00444080
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
NCT01428193
Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients
NCT00395291
Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer
NCT00731952
Glucose Regulation in Acute Stroke Patients (GRASP) Study
NCT00282867
Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography
NCT00591669
Blood Glucose Awareness Training for Parents
NCT00315991
Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals
NCT00300742
Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus
NCT00943787
Comprehensive Magnetic Resonance of Peripheral Arterial Disease
NCT00587678
Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
NCT00304096
Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)
NCT00252239
Impact of Heart Rate Characteristics Monitoring in Neonates
NCT00307333
Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)
NCT00599651
Cost Effectiveness and Efficacy of Kyphoplasty and Vertebroplasty Trial
NCT00279877
Feasibility and Efficacy of Delivering Blood Glucose Awareness Training Over the Internet
NCT00327210
Effects of Lumbosacral Joint Mobilization/Manipulation on Lower Extremity Muscle Neuromuscular Response
NCT00601341
Effects of Intravenous Local Anesthetic on Bowel Function After Colectomy
NCT00600158
Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls
NCT01773772
Factors Influencing the Racial Disparity in Sudden Infant Death Syndrome (SIDS)
NCT01361893
Effects of Electrical Stimulation on Osteoarthritis of the Knee
NCT00601497
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00114192
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
NCT00091273
Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38
NCT00912574
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
NCT00114270
Internet-based Treatment of Early Childhood Fecal Incontinence
NCT00067769
Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion
NCT00114205
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
NCT00089219
Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00114153
Bone Accrual and Hormones in Response to Lactation
NCT01563094
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
NCT00089206
Impact of Gender on Hospitalized Patients
NCT00843557
Lifestyle Intervention's Impact on Health Care Costs
NCT00717158
Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults
NCT00474279
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
NCT00003222
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00003224
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
NCT00265928
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 58 |
| Phase 2 | 51 |
| Phase 3 | 14 |
| Phase 4 | 26 |
Therapeutic Areas
What is open in the University of Virginia pipeline
101 recruiting of 449 indexed (22% open); 281 completed (63%).
Phase mix: 40 late (III/IV) vs 109 early (I/II) (early-phase heavy).
Top condition: Type 1 Diabetes Mellitus (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Virginia: open-pipeline peers nationwide
Peers matched on 449 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 449 trials (± recruiting share)
- Medical College of Wisconsin · 447 trials · 21% recruiting
- Alliance for Clinical Trials in Oncology · 446 trials · 7% recruiting
- Boston Children's Hospital · 462 trials · 24% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Ohio State University Comprehensive Cancer Center · 23% recruiting · 341 trials
- University of Delaware · 23% recruiting · 106 trials
- University of Oklahoma · 22% recruiting · 358 trials
- ALX Oncology · 22% recruiting · 9 trials
Related
What to do with this University of Virginia page
449 registered trials is a research-attention snapshot, not an endorsement of University of Virginia or any single study.
- 101 of University of Virginia's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 1 Diabetes Mellitus is the condition University of Virginia studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Virginia pipeline card: 449 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.